One in three men over 15 globally have at least one incidence of genital HPV, underscoring the need to include males in HPV prevention strategies. The prevalence remains high from young adulthood through later life, particularly for high-risk HPV types linked to cancers.
Booster launches to develop proteasome activator medicines
The company will focus on creating small molecule therapeutics that enhance the natural function of proteasomes. Credit: Gorodenkoff/Shutterstock. Booster Therapeutics has announced its inception, backed
October 11, 2024